Pharmaceutical composition for treating retinopathy
By using nanoemulsions of insulin, DHA and Coenzyme Q10, the complexity and side effects of surgical in the treatment of retinopathy in premature infants were solved, and the healthy growth of retinal blood vessels and vision improvement was achieved, retinal bleeding and neovascularization were reduced, and the Oxidative stress and inflammation.
Patent Information
- Application Number
- CN202411389357.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-05-28
- Filing Date
- 2020-05-27
- Publication Date
- 2024-11-19
AI Technical Summary
The existing treatment methods for retinopathy (ROP) in premature infants have surgical complexity and side effects, and there is a lack of effective local treatment options for damage to retinal tissue.
Nanoemulsions containing insulin, docosahexaenoic acid (DHA) and Coenzyme Q10 are used to promote physiological vascular development, reduce retinal hemorrhage and neovascularization, reduce oxidative stress, and improve retinal layer development through local administration.
Effectively stimulate healthy vascular growth, reduce retinal bleeding and pathological vascular growth, reduce intraocular toxicity, improve retinal vascular coverage and layer development, reduce inflammation, and reduce the incidence of visual impairment.
Smart Images

Figure CN118975984A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application is a divisional application of application number 202080050690.5, application date May 27, 2020, and invention name “Compositions and methods for treating retinopathy”. Technical Field
[0003] The present invention relates to a material composition for treating retinopathy. Embodiments of the present invention relate to a nanoemulsion comprising insulin and / or IGF for treating retinopathy of prematurity (ROP). Background Art
[0004] When birth occurs before 37 weeks of pregnancy, it is considered premature or preterm. The last few weeks in the womb are critical for healthy weight gain and adequate development of various vital organs.
[0005] In humans, the retina develops in an area where tissue oxygen levels are low. Vascular precursor cells are laid down from 12 to 21 gestational ages, providing a scaffold for future vascular development. Retinal angiogenesis begins at approximately 16 weeks of gestational age, with new vessels sprouting from existing vessels. The metabolic demands of the developing retina exceed the oxygen provided by the choroidal circulation, resulting in "physiological hypoxia," which stimulates angiogenesis.
[0006] Retinopathy of prematurity (ROP) is a developmental vascular disease characterized by abnormal growth of retinal blood vessels in an incompletely vascularized retina. ROP occurs primarily in extremely low gestational age neonates (ELGANS) weighing less than 1250 g at birth or less than 28 weeks of gestational age, and is the most common cause of visual impairment and blindness in children.
[0007] Current treatment options, including laser photocoagulation and intravitreal injections of vascular endothelial growth factor (VEGF) antibodies, have been shown to be effective for severe, advanced ROP. However, laser photocoagulation destroys a major portion of the retina, making it a difficult and complex procedure for young infants, while intravitreal injections of VEGF antibodies may cause systemic inhibition of blood vessel growth that affects other organs.
[0008] Therefore, it would be necessary and highly advantageous to have a method for treating retinopathy that does not have the above limitations. Summary of the invention
[0009] According to one aspect of the present invention, a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10 is provided.
[0010] According to another aspect of the present invention, a method for treating retinopathy of prematurity is provided, the method comprising administering a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10 to the eyes of a premature infant, thereby treating retinopathy of prematurity.
[0011] According to another aspect of the present invention, a method for preventing or reducing the severity of retinopathy of prematurity is provided, the method comprising administering a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10 to the eyes of a premature infant, thereby preventing or reducing the severity of retinopathy of prematurity.
[0012] According to another aspect of the present invention, a method for reducing retinal hemorrhage in premature infants is provided, the method comprising administering a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10 to the eyes of premature infants, thereby reducing retinal hemorrhage in premature infants.
[0013] According to another aspect of the present invention, a method for reducing retinal hemorrhage in a subject experiencing retinopathy is provided, the method comprising administering a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10 to the subject's eye, thereby reducing retinal hemorrhage in the subject's eye.
[0014] According to another aspect of the present invention, a method for reducing retinal neovascularization in a subject experiencing retinopathy is provided, the method comprising administering to the subject's eye a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10, thereby reducing retinal neovascularization in the subject's eye.
[0015] According to another aspect of the present invention, a method for increasing retinal vascular coverage in premature infants is provided, the method comprising administering a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10 to the eyes of the premature infant, thereby increasing the retinal vascular coverage (reducing the avascular retinal area) of the premature infant.
[0016] According to another aspect of the present invention, a method for reducing retinal inflammation in premature infants is provided, the method comprising administering a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10 to the eyes of the premature infants, thereby reducing retinal inflammation in the premature infants.
[0017] According to another aspect of the present invention, a method for reducing retinal oxidative stress in premature infants is provided, the method comprising administering a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10 to the eyes of the premature infant, thereby reducing retinal oxidative stress in the premature infant.
[0018] According to another aspect of the present invention, a method for improving the development of retinal layers in premature infants is provided, the method comprising administering a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10 to the eyes of the premature infant, thereby improving the development of the retinal layers in the premature infant.
[0019] According to another aspect of the present invention, a method for reducing visual impairment (incidence or severity) in premature infants is provided, the method comprising administering a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10 to the eyes of the premature infant, thereby reducing visual impairment in the premature infant.
[0020] According to another aspect of the present invention, a method for increasing the visual field of a premature infant is provided, the method comprising administering a pharmaceutical composition comprising insulin, docosahexaenoic acid (DHA) and coenzyme Q10 to the eyes of the premature infant, thereby increasing the visual field of the premature infant.
[0021] According to another aspect of the present invention, there is provided a method for preparing a pharmaceutical composition for topical treatment of retinopathy, the method comprising the steps of: (a) generating an oil-in-water nanoemulsion comprising docosahexaenoic acid (DHA) and coenzyme Q10 in an oil phase; and (b) combining insulin or IGF-1 with nanodroplets of the nanoemulsion using an amine coupling reaction.
[0022] Unless otherwise defined, all technical and scientific terms used in this application have the same meanings as those generally understood by those of ordinary skill in the art to which the invention belongs. Although methods and materials similar or equivalent to the methods and materials described in this application can be used in the practice or testing of the present invention, suitable methods and materials are described below. In the event of a conflict, the patent specification (including definitions) shall prevail. In addition, materials, methods and examples are illustrative only and are not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The present invention is described herein by way of example only with reference to the accompanying drawings. With specific reference now to the accompanying drawings, it is emphasized that the details shown are exemplary and are only for the purpose of illustrative discussion of the preferred embodiments of the present invention, and are presented in order to provide what is considered to be the most useful and most easily understood description of the principles and conceptual aspects of the present invention. In this regard, no attempt is made to show the structural details of the present invention in more detail than is necessary for a basic understanding of the present invention, and the description in conjunction with the accompanying drawings makes it clear to those skilled in the art how several forms of the present invention may be implemented in practice.
[0024] In the attached figure:
[0025] Figure 1 The composition of the invention is schematically shown.
[0026] Figure 2A -B is the total amount of retinal hemorrhage ( Figure 2A ) and total severe bleeding ( Figure 2B ) in vivo funduscopy findings.
[0027] Figure 3A -C is a normoxic animal ( Figure 3A ), untreated hypoxic animals ( Figure 3B ) and therapy animals ( Figure 3C ) in vivo funduscopy findings.
[0028] Figure 4A - B is a graph showing the effect of treatment on neovascularization at days 14 and 18.
[0029] Figure 5A -D shows insulin treatment group ( Figure 5A ), IGF-1 treatment group ( Figure 5B ), untreated group ( Figure 5C ) and normal (healthy) animals ( Figure 5D ) of P14 stained with isolectin-B4.
[0030] Fig. 6A -B is a graph showing the avascular area of the insulin-treated group, the IGF-1-treated group, the untreated group, and the normoxic group.
[0031] Fig. 7A -D shows the insulin group (Figure 7), IGF-1 group ( Figure 7B ), untreated group ( Figure 7C ) and normoxic group ( Fig.7D ) isolectin-B4 stained images of P14. ROI (green), vascular coverage area (blue), vascular skeleton (red) and branch points (white) are marked.
[0032] Figure 8It is a chromatogram of the conjugation reaction at a specific time point with all reaction components, such as reactants (rh-insulin and DHA), intermediates (DHA-EDC intermediate), and resulting products (insulin-DHA conjugate).
[0033] Fig. 9 is a chromatogram of insulin-DHA conjugate extracted from the lyophilized emulsion (finished formulation).
[0034] Fig.10 is a chromatogram showing the peaks of the components of the lyophilized emulsion (finished formulation).
[0035] Fig.11A -C is the result of automatic analysis of H&E retinal layer thickness using Wimretina software ( Fig.11A ), the results of the analysis of the biomarker PGE2 levels performed in the study, and the comparison of the different study groups ( Fig. 11B ) and the results of the analysis of the biomarker 8-iso-PGF2a levels performed in the study, comparing the different study groups ( Fig. 11C )’s picture.
[0036] Figure 12-13 It is a chromatogram showing peaks of components of a preparation containing free insulin, DHA, and coenzyme Q10.
[0037] Fig.14A 15A-E and 15A-E are cryogenic transmission electron micrographs (TEM) of compositions of the present invention. DETAILED DESCRIPTION
[0038] The present invention is a composition of matter that can be used to treat retinopathy. Specifically, the present invention can be used to treat ROP by topical administration of a nanoemulsion containing insulin or IGF.
[0039] The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions.
[0040] Before describing in detail at least one embodiment of the present invention, it should be understood that the application of the present invention is not limited to the details set forth in the following description or the details shown in the embodiments. The present invention can have other embodiments, or can be implemented or executed in various ways. In addition, it should be understood that the words and terms used in this application are only for descriptive purposes and should not be considered as limiting.
[0041] While treatment options for ROP exist, such options are limited by administration complexity, side effects, and potential damage to ocular tissue.
[0042] The inventors hypothesized that an effective treatment for ROP would prevent postnatal toxic influences (eg, oxygen overdose) and provide missing intrauterine factors (insulin and insulin growth factor 1) that could promote physiological vasculature development while minimizing systemic exposure to these factors.
[0043] While implementing the present invention, the composition formulated by the inventors can promote the development of physiological ocular vasculature and reduce intraocular toxicity, thereby being able to treat retinal diseases, such as retinopathy. As further described in the Examples section below, the composition of the present invention can effectively stimulate healthy blood vessel growth and prevent and reduce retinal hemorrhage and pathological blood vessel growth (neovascularization) caused by oxygen-induced rat models.
[0044] The term "promoting physiological vascularization" refers to increasing the flow or passage of oxygen from the optic nerve to the periorbital area.
[0045] The term "retinopathy" refers to any damage to the retina that may result in visual impairment. This may include, for example, pathologies that slow or prevent the growth of physiological vasculature (vascular occlusion or constriction phases, such as stage I of ROP) and abnormal (abnormal) pathological blood vessels that form in response to tissue hypoxia and ischemia. Retinopathy may be caused by external factors such as radiation or head trauma, or it may be a manifestation of systemic diseases such as diabetes or hypertension. Retinopathy can also be caused by vascular inflammation and drugs (e.g., diabetes drugs such as exenatide, liraglutide, and pramlintide).
[0046] Therefore, according to one aspect of the present invention, there is provided a composition of matter comprising a therapeutically effective amount of insulin and / or IGF-1, docosahexaenoic acid (DHA) and coenzyme Q10 as active ingredients.
[0047] As further described herein, insulin and / or IGF-1 promote physiological vascular development, while DHA reduces inflammatory responses and Coenzyme Q10 reduces oxidative stress signaling.
[0048] The term "therapeutically effective amount" or "pharmaceutically effective amount" means a dosage of an active ingredient or a composition comprising the active ingredient that will provide the therapeutic effect indicated for the active ingredient.
[0049] The dosage of each active ingredient in the pharmaceutical composition of the present invention may depend on a number of factors, including the subject being treated, the stage of retinopathy (eg, ROP), and the route of administration (topical or intraocular).
[0050] In the case of ROP, progression may be determined by somatic effects (eg, vascular density and coverage), degree and / or progression of vascularization, or the quality of retinal layer development.
[0051] The composition of matter can be formulated as a water-in-oil nanoemulsion having nanodroplets comprising docosahexaenoic acid (DHA) and coenzyme Q10, bound to insulin and / or insulin-like growth factor (eg, via an amide bond). Figure 1 is a schematic diagram of a composition of matter of the present invention, showing nanodroplets bound to insulin or IGF12 and containing DHA12 and coenzyme Q1014.
[0052] The following Examples section describes a method for preparing the compositions of matter of the present invention.
[0053] The composition of matter can be stored in a lyophilized state and reconstituted with water or saline, for example, for use or stored as a ready-to-use pharmaceutical composition.
[0054] The composition of matter may be part of a pharmaceutical composition comprising a carrier for topical or intraocular delivery.
[0055] Topical formulations of the pharmaceutical compositions of the present invention may include carriers such as medium chain triglycerides (MCT), long chain triglyceride oils such as castor oil, synthetic and semi-synthetic oils such as mineral oil, and unsaturated fatty acids such as oleic acid.
[0056] The intraocular preparation of the pharmaceutical composition of the present invention may be prepared as a microemulsion and / or contain carriers such as liposomes, nanospheres, micelles and nanocapsules.
[0057] Intraocular preparations can be formulated to slow or delay the release of the active ingredient using excipients that form inclusion complexes with the active ingredient, such as chelating agents, surfactants, and cyclodextrins.
[0058] The pharmaceutical composition may further comprise:
[0059] (i) Carbohydrates (as stabilizers, lubricants or coolants), including but not limited to monosaccharides (e.g. glucose, maltose), disaccharides (e.g. trehalose), oligosaccharides (dextrins (e.g. maltodextrin), cyclodextrins (e.g. hydroxypropyl-β-cyclodextrin (HPbCD)), polysaccharides (e.g. dextran).
[0060] (ii) Emulsifiers, including but not limited to nonionic surfactants of natural origin (e.g., lecithin, egg yolk phospholipids) and nonionic surfactants of synthetic origin (e.g., Tyloxapol) and ionic surfactants (e.g., cetalkonium chloride).
[0061] (iii) thickeners, including but not limited to hydrophilic polymers such as polyvinyl alcohol or cellulose derivatives such as hydroxypropyl methylcellulose (HPMC).
[0062] (iv) Bioadhesives, such as polyamino acids (eg gelatin, human albumin) and polysaccharides (eg cellulose derivatives (eg hydroxypropyl methylcellulose (HPMC) and hydroxypropyl cellulose (HPC)), hyaluronic acid).
[0063] (v) Gelling agents, such as alginates and polyacrylates, may be added to the pharmaceutical composition to increase the residence time of the active ingredient on the cornea.
[0064] According to an embodiment of the present invention, the concentration of insulin in the pharmaceutical composition may be 0.001 U / ml to 20 U / ml, and the concentration of IGF may be 0.001 U / ml to 20 U / ml.
[0065] According to an embodiment of the present invention, the concentration of DHA in the pharmaceutical composition may be 1 mg / ml to 4 mg / ml.
[0066] According to an embodiment of the present invention, the concentration of Coenzyme Q10 in the pharmaceutical composition may be 1 mg / ml to 3 mg / ml.
[0067] Table 1 below describes the topical formulations of the present compositions.
[0068] Table 1 - Topical Preparations
[0069]
[0070] This formulation can be modified to be free of MCT and contain two forms of DHA, such as free acid and ethyl ester. These two forms of DHA replace the MCT in the core of the droplets. Two separate emulsions are produced and combined in the last production step. One emulsion contains droplets containing DHA free acid combined with insulin. The second emulsion contains droplets in which Q10 is incorporated into the DHA ethyl ester core. Table 2 below lists the ingredients of this embodiment of the formulation of the present invention in injectable form.
[0071] Table 2
[0072]
[0073] *Contains about 0.4mg / ml DHA free acid and about 1.6mg / ml DHA ethyl ester (equivalent to 1.47mg / ml
[0074] DHA free acid).
[0075] **Sodium hydroxide or hydrochloric acid is used to adjust pH and is not included in the total.
[0076] Table 3 below describes the intraocular formulations of the compositions of the present invention.
[0077] Table 3 - Intraocular Preparations
[0078]
[0079] In order to enhance the efficacy of the composition of the present invention, a method for preparing a nanoemulsion having nanodroplets encapsulating (DHA) and coenzyme Q10 and binding to insulin or insulin-like growth factor was developed.
[0080] Therefore, according to another aspect of the present invention, a method for preparing a pharmaceutical composition for topical treatment of retinopathy is provided. The pharmaceutical composition is prepared by generating an oil-in-water nanoemulsion comprising docosahexaenoic acid (DHA) and coenzyme Q10 in an oil phase, and combining insulin or IGF-1 with nanodroplets of the nanoemulsion using an amine coupling reaction.
[0081] After the nanoemulsion is formed, the nanodroplets can be purified or concentrated using, but not limited to, column chromatography, tangential flow filtration (TFF), dialysis. Stabilizers such as, but not limited to, cyclodextrin, dextrin, monosaccharide or disaccharide can be added.
[0082] The formulation is then lyophilized for storage and subsequently reconstituted with saline or water before use.
[0083] A more detailed description of the present formulation method is provided in the Examples section below.
[0084] As mentioned above, the composition of the present invention can be used to treat retinopathy, especially retinopathy of prematurity (ROP).
[0085] Therefore, according to another aspect of the present invention, a method for treating a retinopathy in a subject in need (e.g., a premature infant) is provided. The method is achieved by administering a pharmaceutical composition of the present invention to the eyes of a subject in need. This administration can be topical or intraocular.
[0086] The term "subject in need" as used in this application refers to a human or non-human mammal. Humans or non-human mammals (cats, dogs, cattle, sheep, pigs, goats and horses) of any age (e.g., infants (such as full-term or premature infants), adults or the elderly) or gender. The human subject can be a premature infant with a gestational age of 24 to 33 weeks. The subject can also be a low birth weight infant weighing between 500 grams and 1650 grams at birth.
[0087] The topical preparation (eye drops) of the composition of the present invention can be applied to premature infants at any time period from birth to six months old, once or several times a day for 180 days, with a dose of 10 μL to 100 μL. The intraocular preparation of the composition of the present invention can be applied to premature infants at any time period from birth to six months old, once every few weeks for 180 days according to clinical needs, with a dose of 5-30 microliters per injection.
[0088] As used herein, the term "about" refers to ± 10%.
[0089] Other objects, advantages and novel features of the present invention will become apparent to one of ordinary skill in the art upon examination of the following examples, which are not intended to be limiting.
[0090] Example
[0091] Reference is now made to the following examples, which together with the above descriptions illustrate the invention in a non limiting fashion.
[0092] Example 1
[0093] Nanoemulsion formulations
[0094] The following examples illustrate the preparation of compositions of matter of the present invention formulated as lyophilized powders suitable for reconstitution as oil-in-water nanoemulsions.
[0095] Table 4 below lists the ingredients used in the production of the composition of matter formulation.
[0096] Table 4 - Preparation ingredients
[0097]
[0098] 1 Example 1 describes certain production processes for insulin-containing formulations.
[0099] 2 Removed from the process.
[0100] 3 Cross-linking agent, used in amine coupling reactions and subsequently removed.
[0101] Nanodroplets were prepared by solvent replacement. 100 mg CoQ10, 50 mg CoQ10, 25 mg Tyloxapol and 50 mg MCT were dissolved in 9 ml acetone, and 25 mg Lipoid E 80 was dissolved in 1 ml ethanol. The resulting solutions were combined, mixed at 900 rpm for 30 minutes at room temperature, and added dropwise to 20 ml of 0.1% w / v aqueous polyvinyl alcohol solution, and stirring was continued at 900 rpm for 15 minutes. Then, the organic solvent was completely removed using a laboratory rotary evaporator at room temperature and reduced pressure (50 mBar), and the resulting emulsion was subjected to an amine coupling reaction after the initial pH was adjusted to 7.4 with 0.5 M NaOH.
[0102] 1.3 μmol EDC prepared in 0.5 ml phosphate buffered saline (pH 7.2) was added to the obtained emulsion, and the obtained mixture was incubated at room temperature for 15 minutes, and then the pH was adjusted to 8.3 ± 0.2 using sodium carbonate buffer. 0.5 ml 0.1 mol / ml rh-insulin phosphate buffered saline solution (pH 7.2) was added to 19.5 ml emulsion. The reaction mixture was stirred at room temperature for 12 hours. Then, using water as eluent, the reaction mixture was loaded onto a gravity flow PD-10 gel filtration column (Sephadex G-25) to separate nanodroplets from smaller particles (e.g. EDC, free active substance molecules). Excess eluent (water) was removed from the nanodroplet fraction under reduced pressure (50 mbar (mBar)) and 37 ° C using a laboratory rotary evaporator. The emulsion was then mixed with 2-hydroxypropyl-β-cyclodextrin to a final concentration of 2% w / v, filtered through a 0.45 μm PES (polyethersulfone) membrane, dispensed into vials and freeze-dried. The content of active ingredients in 1 ml of the reconstituted solution was 0.67 U rh-insulin, 2 mg DHA and 1 mg CoQ10.
[0103] Example 2
[0104] Study 1
[0105] An ophthalmic formulation of the composition of matter described in Example 1 (ELGN01 consisting of insulin DHA and Coq10) was tested on a rat oxygen-induced retinopathy model.
[0106] program
[0107] A group of rats, including 18 pups from one litter, was divided into two groups: Group A - ELGN01 group (9 pups), Group B - untreated (9 pups, untreated in an oxygen chamber). One mother rat, 3 pups, was placed in normoxic conditions as an additional control.
[0108] Treatment was started on days 5-14 or 18 (depending on the day of sacrifice), first by administration under the eyelid via syringe (topical, without damaging the eye), then by instillation of eye drops after opening the eye.
[0109] The oxygen therapy regimen was as follows: 24-hour cycles of high oxygen (50%) followed by 24-hour cycles of low oxygen (12%) from days 0 to 14 of life.
[0110] The study ended at postnatal day 14 (P14) for group 1 and at postnatal day 18 (P18) for group 2. Fundus ophthalmologists performed fundus examination evaluation on day 17, and samples were then evaluated histologically and immunohistologically.
[0111] result
[0112] Results of basic in vivo examination
[0113] A total of 12 retinal hemorrhages were observed in the treated group compared to 22 in the untreated animals (ELGN01 treatment, significant P = 0.04).
[0114] Table 5 - In vivo results of fundus examination - retinal hemorrhage per group
[0115] Treatment-ELGN01 Untreated Normoxia The number of all retinal hemorrhages 12* 22 0 Number of severe retinal hemorrhages (medium to large) 1 11 0 Average number of retinal hemorrhages per eye 1.4 2.75 0
[0116] Data are mean ± SD; (*)p<0.05, (**)p<0.01.
[0117] The total amount of retinal damage and severe hemorrhage in the treated and untreated groups was as follows Figure 2A -B.
[0118] Figure 3A -C is a picture of the retina in normoxia and hypoxia (treated and untreated). The retinal blood vessels of normal animals are intact, without hemorrhage or ablation. Untreated hypoxic animals have retinal hemorrhages (arrows). Animals treated with the drug show reduced damage.
[0119] Neovascularization area
[0120] Effects on angiogenesis Figure 4A -B. Neovascularization (NV) was higher at P18, corresponding to the end of stage II of the human disease. P14 corresponds to the end of stage I of the disease (progression stage). At both time points, NV was significantly lower in the treated groups than in the untreated animals. At P14, the ELGN01-treated group showed 0% neovascularization, compared to 0.09% in the untreated group (T-test comparison P=0.07). At P18, the ELGN01-treated group showed an average of 40% less neovascularization compared to the untreated group (ELGN01-treated 1.35%, untreated 1.89%, t-test comparison P=0.07, treatment effect 28%).
[0121] Retinal layers
[0122] Paraffin-embedded whole eyes were sectioned and stained with hematoxylin and eosin. Four sections from different locations were collected on one slide. H&E staining was imaged using a light microscope with a 10x objective (4x objective for some locations).
[0123] Representative staining from the untreated OIR group shows disorganization of retinal layers, with thickening of the ganglion cell layer as a result of OIR injury. A total of 8 samples were available for each group - 4 sections / eye, 2 eyes per treatment group (from different animals).
[0124] To assess the integrity of the retinal layers, de-identified H&E stained images were uploaded into Wimsis software image. Masking analysis was performed on each retina to identify and measure the size of each retinal layer - RGCL-retinal ganglion cell layer, IPL-inner plexiform layer, INL-inner nuclear layer, OPL-outer plexiform layer, ONL-outer nuclear layer, RPE-retinal pigment epithelium, CHO-choroid. Fig.11A The average thickness of the retinal layers is shown.
[0125] Table 6 - Average thickness of retinal layers [px]
[0126]
[0127] Example 3
[0128] Study 2
[0129] Ophthalmic formulations based on the composition of matter described in Example 1 (ELGN01 consisting of insulin DHA and Coq10, ELGN02 consisting of IGF-01 and its analogs) were tested in the rat oxygen-induced retinopathy model.
[0130] program
[0131] Two groups of rats, each including 18 pups, were divided into three treatment groups: Group A ELGN01 (12 pups), Group B ELGN02 (12 pups), Group C untreated (12 pups). Group D was the normal control group.
[0132] Treatment started on day 5 and animals were treated until day 14 or 18 (depending on the day of sacrifice), first by syringe (topical, non-invasive) under the eyelid and then by eye drops after eye opening.
[0133] The oxygen therapy regimen was as follows: 8 intermittent hypoxic episodes within the first 4 days, 3 drops to 12% within 30 minutes, and 50% hyperoxia the rest of the time. Days 5-14 of life, 24-hour cycles of hyperoxia (50%) followed by 24-hour hypoxia (12%).
[0134] The study ended on day 14 of life for group 1, with fundus examination evaluation by an ophthalmologist on day 17, followed by histological and immunohistological evaluation of samples.
[0135] result
[0136] Isolectin staining
[0137] Samples were flat mounted and retinas were stained with isolectin IB 4. Avascular areas (AVAs) were manually quantified by an independent expert using images of isolectin-stained retinas.
[0138] Figure 5A -D shows the staining of insulin and IGF-1 treated groups, untreated group and normoxic group. Figure 5A -B), minimal avascular areas with intact central vessels were observed. Figure 5C ), a large avascular area was observed (arrow). Figure 5D ), complete coverage of the blood vessels was observed.
[0139] Fig. 6A -B is a graph showing AVA. At P14, AVA was 50% lower in both treatment groups compared to the control group (percent avascular area: ELGN01 treated: 2.77%, ELGN02 treated: 3.15%, untreated: 6.13%). The normoxic group accounted for 1.4% of the avascular area. When comparing the treated groups to untreated animals using the T test, there was a statistically significant difference in the ELGN01 treated group compared to untreated animals (P=0.01). There was also a statistically significant difference in the ELGN02 treated group compared to untreated animals (p=0.03).
[0140] Each retina was analyzed in a masked manner for vessel density (%, calculated by dividing the number of pixels of a vessel by the total number of pixels in the region of interest), total vessel area, number of branch points (where two or more segments converge), number of segments (number of individual vessel segments), and mean segment length.
[0141] At P14, both treatment groups outperformed untreated animals in many ways; the vessel density (%) was significantly higher in the ELGN01-treated group (P=0.051) and significantly higher in the ELGN02-treated group (P=0.032) compared to the untreated group, indicating better retinal vascular growth and development, with fewer avascular areas. The treated groups also showed greater vessel area compared to the untreated group - the ELGN01-treated group (P=0.073) and the ELGN02-treated group (P=0.014). In addition, the mean segment length was significantly longer in treatment A-ELGN01 compared to untreated animals (P=0.037), indicating better continuity of the vessels.
[0142] Table 7-Amount of retinal blood vessels at P14
[0143]
[0144] Data are mean ± SD; compared with the untreated control group, (*) p<0.05, (**) p<0.01. N=5 per group.
[0145] Fig. 7A-D is the isolectin-B4 staining image of P14 of each treatment group. ROI (green), vascular coverage area (blue), vascular skeleton (red) and branch points (white) are marked.
[0146] As shown in Table 8 below, at P18, the vascular density (%) was significantly higher in the ELGN01 treated group than in the untreated group (P=0.007). The ELGN02 treated group showed no significant trend. The vascular density % reflects the amount of retina that is vascularized compared to the non-vascularized area. A higher density of vessels without neovascularization indicates better retinal vascular growth and less avascular area. The vascular area was larger in the treated group compared to the untreated group. The ELGN01 treated group showed more branch points compared to the untreated group (P=0.02). In addition, the ELGN01 treated group showed more blood vessels compared to the untreated group (P=0.04).
[0147] Table 8-Amount of retinal blood vessels at P18
[0148]
[0149]
[0150] Data are mean ± SD; compared with the untreated control group, (*) p<0.05, (**) p<0.01. N=5 per group.
[0151] Biomarker activity
[0152] At P14 and P18, eyes were collected, homogenized and centrifuged to compare the levels of different biomarkers in the tissues of the different study groups. The samples included 4 different rats per group, and every 3 samples were tested. The contents were normalized to the total protein concentration in each sample. The biomarker analyzed was 8-isoprostane (8-isoprostane) or 8-isoPGF2α (8-isoPGF2α), a commonly studied biomarker that is produced in large quantities during oxidative stress and lipid peroxidation and is a reliable and proven biomarker of oxidative stress (Beharry, 2017). In addition, PGE2- a biomarker of inflammatory processes with dual opposing effects on endothelial cells ( Fig. 11B ). It mediates vasoconstriction and vasodilation through different receptors. PGE2 is the main metabolite of COX-2 isoform, which is activated by cytokines and growth factors and is highly involved in angiogenesis (Beharry, 2017).
[0153] The results showed that 8-isoPGF2α levels were reduced at P14 and P18 compared with the untreated group, indicating a preventive effect on oxidative stress damage in the animal model ( Fig. 11C ). This effect was seen in the first and second stages of the disease (P14 and P18). At P14, PGE2 levels were higher in all groups than in the normoxic group, and at P18, the treated groups showed a decrease, with the untreated group showing a significant increase, which was associated with the inflammatory stage of the pathology ( Fig. 11B ).
[0154] Example 4
[0155] Study 3
[0156] An ophthalmic formulation (ELGN01 comprising insulin, DHA and Coq10 (described in Example 1)) was administered to neonatal rats to determine the insulin concentration in the eye after administration.
[0157] program
[0158] Two groups of rats, each including 18 pups, were divided into two treatment groups: Group A - ELGN01 normoxic group (18 rats), Group B - ELGN01 hypoxic group (18 rats). A group of rats including 2 pups under normoxic conditions served as controls.
[0159] The composition (containing 0.0067 insulin units at a dose of 10 g / L) was applied under the eyelid using a syringe (topical), and treatment was started on day 5 and continued for 4 days. Rats (each T, N=3) were killed 30, 60, and 120 minutes after administration. Whole eyes were homogenized and analyzed by ELISA ( ELISA) was used for evaluation.
[0160] result
[0161] The results shown in Table 9 below indicate that 8-16% of the insulin was absorbed into the ocular tissue within 2 hours after administration.
[0162] Table 9 - Mean values (±SDV) at each time point
[0163] time Insulin concentration (Pmol / L) 30 5.52±2.05 60 4.66±0.92 120 4.80±1.15
[0164] Example 5
[0165] Nanoemulsion formulations
[0166] The following examples illustrate alternative methods of preparing the compositions of matter of the present invention.
[0167] The invention discloses a one-pot combination of insulin directly with oily nanodroplets during the preparation process. Insulin is coupled to the carboxyl group of DHA in one step in an aqueous medium using a cross-linking reagent N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC).
[0168] The method for preparing insulin-DHA conjugates employs the following general steps:
[0169] - Formation of nanodroplets using solvent displacement method;
[0170] - Activation of DHA carboxyl groups with EDC by forming active O-acylisourea DHA-EDC esters;
[0171] -Insulin binds to the carboxyl group of DHA by forming an amide bond with the primary amine group of insulin, while releasing the EDC byproduct, namely soluble N-unsubstituted urea.
[0172] The reaction mixture was purified from the EDC byproduct by ultrafiltration through a 30,000-100,000 MWCO membrane.
[0173] Materials and methods
[0174] Preparation of organic phase - 347 mg DHA free acid, 75 mg tyloxapol and 75 mg Lipoid E 80 were dissolved in 25 ml ethanol. The mixture was added dropwise through a 21G needle into 100 ml of double layer deionized water, with continuous mixing at 350 RPM at room temperature. The resulting emulsion was mixed for another 10 minutes, and then the organic solvent was completely removed under reduced pressure using a laboratory rotary evaporator (40 ± 2 ° C, 50 mBar).
[0175] After initial adjustment of the pH to 4.5 with 0.1 N HCl, the resulting emulsion was subjected to amine coupling reaction.
[0176] 27 mmol of EDC dissolved in 1 ml of water was added to the resulting emulsion and the mixture was incubated at room temperature for 40 minutes until the formation of the DHA-EDC intermediate ester was complete.
[0177] The pH of the reaction mixture was adjusted to 6.2, and 0.45 mmol insulin dissolved in 50 ml water (pH 7.2) was added. The reaction was completed within one hour, and the pH was maintained at 6.3-6.4 during the coupling. The reaction was monitored by high performance liquid chromatography (Dionex Ultimate 3000). Figure 8 The method conditions and the chromatogram of the reaction mixture at 30 minutes are given in FIG.
[0178] After the reaction was complete, the mixture was diluted 1:2 with a double layer of deionized water and transferred through a 100,000 MW CO Hydrosart ultrafiltration cartridge (Sartorius) using a peristaltic pump.
[0179] The content of insulin conjugate in 150 ml of the obtained retentate was 0.037 mmol, and the yield calculated based on the insulin content was 82%.
[0180] The osmotic pressure of the emulsion is 301mosm / kg.
[0181] The chromatogram of the coupling reaction mixture is shown in Figure 8 , components and conditions are shown in Table 10 below.
[0182] Table 10
[0183]
[0184]
[0185] Another composition of matter was prepared that was formulated as a lyophilized powder suitable for reconstitution into an oil-in-water nanoemulsion. Table 11 below lists the components used in the preparation process.
[0186] Table 11
[0187]
[0188] 1 Removed from the process.
[0189] 2 Cross-linking agent, used in amine coupling reactions and subsequently removed.
[0190] The formulation process involves preparing two separate emulsions: the first emulsion incorporates Coenzyme Q10 into DHA nanodroplets, and the second emulsion includes insulin coupled to the DHA nanodroplets. The emulsions are prepared separately by displacement and combined before the purification step.
[0191] Emulsion 1
[0192] 300 mg of coenzyme Q10, 525 mg of DHA ethyl ester, 125 mg of tyloxapol and 125 mg of lipid E 80 were dissolved in a mixture of 15 ml of acetone and 50 ml of ethanol. The mixture was added dropwise through a 21G needle to 250 ml of 0.1% PVA aqueous solution, with continuous mixing at 350 RPM at room temperature. The resulting emulsion was mixed for another 10 minutes, and then the organic solvent was completely removed under reduced pressure using a laboratory rotary evaporator (40 ± 2°C, 50 mBar).
[0193] Emulsion 2
[0194] 125 mg DHA free acid, 25 mg tyloxapol and 25 mg Lipoid E 80 were dissolved in 12 ml ethanol. The mixture was added dropwise through a 21G needle into 50 ml of double-layer deionized water, with continuous mixing at 350 RPM at room temperature. The resulting emulsion was mixed for another 10 minutes, and then the organic solvent was completely removed under reduced pressure using a laboratory rotary evaporator (40 ± 2 ° C, 50 mbar).
[0195] After initial adjustment of the pH to 4.5 with 0.1 N HCl, the resulting emulsion was subjected to amine coupling reaction.
[0196] 0.11 mmol of EDC dissolved in 1 ml of water was added to the resulting emulsion and the mixture was incubated at room temperature for 1.25 hours until the formation of the DHA-EDC intermediate ester was complete.
[0197] The pH of the reaction mixture was adjusted to 6.2. 0.15 mmol insulin dissolved in 18 ml water (pH 4.2) was added. The reaction was completed within one hour, and the pH was maintained at 6.2-6.4 during the coupling. The reaction was monitored by high performance liquid chromatography (Dionex Ultimate 3000). Figure 8 Method conditions and typical chromatograms of the reaction mixture are given in .
[0198] After the reaction was complete, the mixture was mixed with emulsion #1 and then diluted 1:2 with 0.1% PVA aqueous solution (osmotic pressure <5 mosm / kg) and transferred through a 30,000 MWCO Hydrosart ultrafiltration cassette (Sartorius) using a peristaltic pump, with a final retentate volume of 250 ml (theoretical content of coupled insulin 0.06 mol / ml).
[0199] 4 g of HPBCD dissolved in 8 ml of water was added to 80 ml of the emulsion and the volume was adjusted to 100 ml.
[0200] The emulsion was filtered through a 0.22 μm PES membrane, filled into 4 ml glass vials (0.5 ml each) and lyophilized. The osmotic pressure of the finished product was 376 mosm / kg.
[0201] The theoretical content of insulin conjugate in each bottle was 0.024 μmol / bottle, and the observed content was 0.017 μmol / bottle; the yield of conjugated insulin was 72%.
[0202] The Z-average sizes of the liquid bulk and the dried finished product were 119.9 nm (polydispersity index 0.137) and 243 nm (polydispersity index 0.342), respectively.
[0203] The content of DHA and coenzyme Q10 in the coupled insulin and lyophilized powder was monitored by RP-HPLC. Fig.10 Table 12 below provides the chromatographic conditions used to test the lyophilized formulations.
[0204] Table 12
[0205]
[0206] exist Fig.14A Typical cryogenic transmission electron micrographs (TEM) of the formulation produced as described in Example 5 are shown in 15A-E and 15A-E.
[0207] Example 6
[0208] Gastrointestinal preparations
[0209] An oral emulsion for the topical treatment of intestinal malabsorption in premature infants was produced. The formulation contains three active ingredients: rh-insulin, DHA, and coenzyme Q10. In the reconstituted formulation, insulin is present as free protein, and DHA and coenzyme Q10 are coupled to oil droplets.
[0210] The formulation process includes the following general steps:
[0211] - Formation of DHA and Coenzyme Q10 emulsions using solvent exchange method;
[0212] - Add rh-insulin and cryoprotectant;
[0213] - Filter and freeze dry.
[0214] Materials and methods
[0215] 513 mg of coenzyme Q10, 898 mg of DHA ethyl ester, 175 mg of tyloxapol and 175 mg of Lipoid E80 were dissolved in 80 ml of ethanol. The mixture was added dropwise through a 21G needle to 350 ml of 0.1% PVA aqueous solution, with continuous mixing at 350 RPM at room temperature. The resulting emulsion was mixed for another 10 minutes, and then the organic solvent was completely removed under reduced pressure using a laboratory rotary evaporator (40 ± 2 ° C, 50 mbar).
[0216] 1 ml of insulin aqueous solution (2.7 mg / ml, pH 8.5) was mixed with 14 ml of a refrigerant solution containing 28.6 mg / ml HPBCD and 343 mg / ml maltodextrin. The resulting solution was added to the continuously mixed emulsion and mixed for 20 minutes.
[0217] The emulsion was filtered through a 0.22um PES membrane, filled into 4ml glass vials (filling volume 0.5ml / vial) and lyophilized. The osmotic pressure of the finished product was 358mosm / kg. Each vial contained 0.65IU rh-insulin, 0.9mg DHA and 0.5mg Coenzyme Q10.
[0218] Table 13 below lists the formulation ingredients. The chromatogram of the lyophilized product is shown in Fig.12 and 13 .
[0219] Table 13
[0220]
[0221] *Sodium hydroxide or hydrochloric acid is used to adjust pH and is not included in the total.
[0222] It should be understood that, for the sake of clarity, certain features of the present invention described in the context of separate embodiments may also be provided in combination in a single embodiment. Conversely, for the sake of brevity, various features of the present invention described in the context of a single embodiment may also be provided separately or in any suitable sub-combination.
[0223] Although the present invention has been described in conjunction with specific embodiments of the present invention, it is obvious that many substitutions, modifications and variations will be apparent to those skilled in the art. Therefore, the present invention is intended to include all of these substitutions, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this application specification are incorporated herein by reference in their entirety to the same extent as each individual publication, patent or patent application is specifically and individually incorporated herein by reference. In addition, the citation or identification of any reference in this application should not be construed as admitting that the reference can be used as the prior art of the present invention.
[0224] In addition, any one or more priority documents of the present application are hereby incorporated by reference into the present application in their entirety.
Claims
1. A pharmaceutical composition, characterized in that The invention comprises: a water-in-oil nanodroplet emulsion for topical delivery, wherein the water-in-oil nanodroplet emulsion for topical delivery comprises an insulin-like growth factor and coenzyme Q10 combined with docosahexaenoic acid amide.
2. The pharmaceutical composition according to claim 1, characterized in that: Also included are vehicles formulated for intraocular delivery.
3. The pharmaceutical composition according to claim 2, characterized in that: The carrier includes a surfactant.
4. The pharmaceutical composition according to claim 1, characterized in that: The concentration of the insulin-like growth factor is 1U to 10U per milliliter.
5. The pharmaceutical composition according to claim 1, characterized in that: The concentration of docosahexaenoic acid is 1 to 3 mg / ml.
6. The pharmaceutical composition according to claim 1, characterized in that: The concentration of the coenzyme Q10 is 1 to 3 mg / ml.
